Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia. | Appl Health Econ Health Policy | 2024 | 37608228 | PubTator, text mining | PubMed |
| CD49d in chronic lymphocytic leukemia: a molecule with multiple regulation layers. Comment to "Sialylation regulates migration in chronic lymphocytic leukemia". | Haematologica | 2024 | 37199129 | PubTator, text mining | PubMed |
| AIRR-C IG Reference Sets: curated sets of immunoglobulin heavy and light chain germline genes. | Front Immunol | 2023 | 38406579 | PubTator, text mining | PubMed |
| Machine learning and multi-omics data in chronic lymphocytic leukemia: the future of precision medicine? | Front Genet | 2023 | 38283149 | PubTator, text mining | PubMed |
| Excess BAFF May Impact HIV-1-Specific Antibodies and May Promote Polyclonal Responses Including Those from First-Line Marginal Zone B-Cell Populations. | Curr Issues Mol Biol | 2023 | 38275663 | PubTator, text mining | PubMed |
| Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia? | Cells | 2023 | 38201234 | PubTator, text mining | PubMed |
| [Advances in clinical research on novel BTK inhibitors for the treatment of chronic lymphocytic leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38185530 | PubTator, text mining | PubMed |
| [Clinical and molecular biological characterization of patients with accelerated chronic lymphocytic leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38185521 | PubTator, text mining | PubMed |
| Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL). | Molecules | 2023 | 38138584 | PubTator, text mining | PubMed |
| Mice Overexpressing Wild-Type RRAS2 Are a Novel Model for Preclinical Testing of Anti-Chronic Lymphocytic Leukemia Therapies. | Cancers (Basel) | 2023 | 38136362 | PubTator, text mining | PubMed |
| Angioimmunoblastic T-Cell Lymphoma after Treatment of Classic Hodgkin Lymphoma: A Case Report. | Hematol Rep | 2023 | 38132275 | PubTator, text mining | PubMed |
| Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib. | Front Oncol | 2023 | 38111528 | PubTator, text mining | PubMed |
| SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode. | Commun Biol | 2023 | 38082099 | PubTator, text mining | PubMed |
| Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials. | Front Immunol | 2023 | 38077330 | PubTator, text mining | PubMed |
| [Expression and Clinical Significance of Helper T Cells 9 and Its Sytokines Interleukin 9 in Chronic Lymphocytic Leukemia]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2023 | 38071043 | PubTator, text mining | PubMed |
| Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience. | Cancers (Basel) | 2023 | 38067296 | PubTator, text mining | PubMed |
| Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials. | Eur J Med Res | 2023 | 38053150 | PubTator, text mining | PubMed |
Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study. | BMC Health Serv Res | 2023 | 38049834 | PubTator, text mining | PubMed |
| Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children. | Front Immunol | 2023 | 38045698 | PubTator, text mining | PubMed |
| Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival. | Clin Transl Med | 2023 | 38037464 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=12